Liquidia Corporation Form 8-K Summary
Business Context and Reporting Period
Liquidia Corporation filed a Current Report on Form 8-K dated December 20, 2023. The filing reports a material legal and regulatory development concerning YUTREPIA and U.S. Patent No. 10,716,793 (the “’793 Patent”).
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Material Developments
- In January 2021, Liquidia petitioned the Patent Trial and Appeal Board (PTAB) for inter partes review of the ’793 Patent.
- In July 2022, the PTAB ruled in Liquidia’s favor, finding all claims of the ’793 Patent unpatentable based on prior art.
- United Therapeutics’ request for rehearing was denied in February 2023.
- United Therapeutics appealed the PTAB decision to the U.S. Court of Appeals for the Federal Circuit in April 2023. Oral argument occurred on December 4, 2023.
- On December 20, 2023, the Federal Circuit affirmed the PTAB’s decision.
Outlook, Risks, and Unusual Items
Following the Federal Circuit decision, Liquidia stated that it would immediately seek to set aside the injunction issued by the U.S. District Court for the District of Delaware in United Therapeutics’ Hatch-Waxman litigation and pursue final U.S. Food and Drug Administration approval of YUTREPIA.
The filing does not state that the injunction has already been lifted or that final FDA approval has been granted. The timing and outcome of those proceedings remain uncertain.
Investor Verification Points
- Verify the Federal Circuit’s affirmance and the scope of the decision regarding the ’793 Patent.
- Monitor Liquidia’s effort to vacate the Delaware injunction.
- Confirm the status, timing, and conditions of YUTREPIA’s FDA approval process.
- Review the related Hatch-Waxman litigation and any subsequent court orders.
- Review Exhibit 99.1, the company’s December 20, 2023 press release, for additional management commentary.